Taiwan
· Delayed Price · Currency is TWD Lumosa Therapeutics Statistics
Total Valuation
TPEX:6535 has a market cap or net worth of TWD 26.18 billion. The enterprise value is 24.85 billion.
| Market Cap | 26.18B |
| Enterprise Value | 24.85B |
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6535 has 168.90 million shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 168.90M |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +2.55% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 6.44% |
| Float | 89.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 668.62 |
| PB Ratio | 13.58 |
| P/TBV Ratio | 13.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -58.50 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -83.73 |
Financial Position
The company has a current ratio of 7.64, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.64 |
| Quick Ratio | 6.92 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,909.73 |
Financial Efficiency
Return on equity (ROE) is -26.03% and return on invested capital (ROIC) is -13.22%.
| Return on Equity (ROE) | -26.03% |
| Return on Assets (ROA) | -11.78% |
| Return on Invested Capital (ROIC) | -13.22% |
| Return on Capital Employed (ROCE) | -18.49% |
| Revenue Per Employee | 910,558 |
| Profits Per Employee | -9.88M |
| Employee Count | 43 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.53% in the last 52 weeks. The beta is 0.16, so TPEX:6535's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -7.53% |
| 50-Day Moving Average | 199.71 |
| 200-Day Moving Average | 248.35 |
| Relative Strength Index (RSI) | 39.41 |
| Average Volume (20 Days) | 327,938 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6535 had revenue of TWD 39.15 million and -424.78 million in losses. Loss per share was -2.60.
| Revenue | 39.15M |
| Gross Profit | 17.71M |
| Operating Income | -357.12M |
| Pretax Income | -436.84M |
| Net Income | -424.78M |
| EBITDA | -353.03M |
| EBIT | -357.12M |
| Loss Per Share | -2.60 |
Balance Sheet
The company has 1.35 billion in cash and 8.48 million in debt, giving a net cash position of 1.34 billion or 7.96 per share.
| Cash & Cash Equivalents | 1.35B |
| Total Debt | 8.48M |
| Net Cash | 1.34B |
| Net Cash Per Share | 7.96 |
| Equity (Book Value) | 1.93B |
| Book Value Per Share | 11.32 |
| Working Capital | 1.34B |
Cash Flow
In the last 12 months, operating cash flow was -296.33 million and capital expenditures -450,000, giving a free cash flow of -296.78 million.
| Operating Cash Flow | -296.33M |
| Capital Expenditures | -450,000 |
| Free Cash Flow | -296.78M |
| FCF Per Share | -1.76 |
Margins
| Gross Margin | 45.24% |
| Operating Margin | -912.09% |
| Pretax Margin | -1,115.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6535 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.64% |
| Shareholder Yield | -0.64% |
| Earnings Yield | -1.62% |
| FCF Yield | -1.13% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TPEX:6535 has an Altman Z-Score of 104.22.
| Altman Z-Score | 104.22 |
| Piotroski F-Score | n/a |